- Conditions
- Macular Degeneration, Age-Related, Geographic Atrophy
- Interventions
- Galegenimab
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 144 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 48
- States / cities
- Bakersfield, California • Encino, California • Fullerton, California + 43 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Dry Age-related Macular Degeneration
- Interventions
- Risuteganib, Sham
- Drug · Other
- Lead sponsor
- Allegro Ophthalmics, LLC
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 7
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Beverly Hills, California + 4 more
- Conditions
- Age-Related Macular Degeneration
- Interventions
- Palomid 529
- Drug
- Lead sponsor
- Paloma Pharmaceuticals, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Choroidal Ischemia, Vitelliform Macular Dystrophy, Age-related Macular Degeneration, Central Serous Retinopathy, Retinitis Pigmentosa
- Interventions
- Sildenafil, Standard of Care Sildenafil, Ocular Coherence Tomography-Angiography (OCT-A), Visual Acuity (VA)
- Drug · Other · Diagnostic Test
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Age-Related Macular Degeneration
- Interventions
- HuCNS-SC sub-retinal transplantation
- Biological
- Lead sponsor
- StemCells, Inc.
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 12
- States / cities
- Tucson, Arizona • Beverly Hills, California • Campbell, California + 9 more
- Conditions
- Age Related Macular Degeneration
- Interventions
- adaptive optics AO-OCT/AF instrument
- Diagnostic Test
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 60 Years to 90 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Choroidal Neovascularization, Macular Degeneration
- Interventions
- Corticosteroid
- Drug
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2000
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- AXT107 Low Dose, AXT107 Mid Dose, AXT107 High Dose
- Drug
- Lead sponsor
- AsclepiX Therapeutics, Inc.
- Industry
- Eligibility
- 50 Years to 99 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 4
- States / cities
- Springfield, Massachusetts • St Louis, Missouri • Asheville, North Carolina + 1 more
- Conditions
- Age Related Macular Degeneration, Geographic Atrophy
- Interventions
- Not listed
- Lead sponsor
- Carl Zeiss Meditec, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 2
- States / cities
- Oakland, California • Jackson, Michigan
- Conditions
- Age-Related Macular Degeneration, Macular Degeneration
- Interventions
- Intravitreal Aflibercept Injection
- Drug
- Lead sponsor
- MidAtlantic Retina
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 3
- States / cities
- Cherry Hill, New Jersey • Huntingdon Valley, Pennsylvania • Philadelphia, Pennsylvania
- Conditions
- Intravitreal Injection, Ocular Rinse, Age-Related Macular Degeneration, Diabetic Macular Edema, Cystoid Macular Edema
- Interventions
- OSDI questionnaire, SPEEDII questionnaire
- Other
- Lead sponsor
- University of Oklahoma
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 142 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Aging, Age-Related Macular Degeneration
- Interventions
- ZeaVision EyePromise Restore, Multivitamin
- Dietary Supplement
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 60 Years to 80 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Age Related Macular Degeneration, Macular Degeneration, AMD
- Interventions
- HuCNS-SC cells
- Drug
- Lead sponsor
- StemCells, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Palo Alto, California • New York, New York + 2 more
- Conditions
- Age-Related Macular Degeneration
- Interventions
- Sirolimus, Standard of Care intravitreal injections of anti-VEGF
- Drug
- Lead sponsor
- Maturi, Raj K., M.D., P.C.
- Individual
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Dry Age-related Macular Degeneration, Geographic Atrophy
- Interventions
- Surgical implantation of the CPCB-RPE1 implant
- Device
- Lead sponsor
- Regenerative Patch Technologies, LLC
- Industry
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2040
- U.S. locations
- 5
- States / cities
- Beverly Hills, California • Huntington Beach, California • Los Angeles, California + 2 more
- Conditions
- Age-Related Macular Degeneration, Geographic Atrophy
- Interventions
- Not listed
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- Placebo, LFG316
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 3
- States / cities
- Phoenix, Arizona • Winter Haven, Florida • Cleveland, Ohio
- Conditions
- Wet Macular Degeneration
- Interventions
- Faricimab, Aflibercept, Sham Procedure
- Drug · Procedure
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 658 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 41
- States / cities
- Phoenix, Arizona • Mountain View, California • Sacramento, California + 36 more
- Conditions
- Age-Related Macular Degeneration, Geographic Atrophy
- Interventions
- smaller incision, new generation implantable miniature telescope (SING-IMT)
- Device
- Lead sponsor
- VisionCare, Inc.
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 10
- States / cities
- Loma Linda, California • Long Beach, California • Sarasota, Florida + 7 more
- Conditions
- Macular Degeneration
- Interventions
- Bevasiranib
- Drug
- Lead sponsor
- OPKO Health, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 23
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Artesia, California + 19 more
- Conditions
- Choroidal Neovascularization
- Interventions
- Faricimab, Ranibizumab, Sham Procedure
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 273 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 52
- States / cities
- Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 46 more
- Conditions
- Recalcitrant Wet Age-related Macular Degeneration
- Interventions
- Ranibizumab
- Drug
- Lead sponsor
- Northern California Retina Vitreous Associates
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- Mountain View, California
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- brolucizumab
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 248 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 5
- States / cities
- Huntington Beach, California • Fort Lauderdale, Florida • Indianapolis, Indiana + 2 more
- Conditions
- Neovascular Age-related Macular Degeneration, Age-Related Macular Degeneration, Wet Macular Degeneration
- Interventions
- bevacizumab, ranibizumab
- Biological
- Lead sponsor
- Outlook Therapeutics, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 61
- States / cities
- Arcadia, California • Bakersfield, California • Beverly Hills, California + 57 more